Back to Search
Start Over
Sensitivity of glioma initiating cells to a monoclonal anti-EGFR antibody therapy under hypoxia
- Source :
- Life Sciences, Life Sciences, Elsevier, 2015, 137, pp.74-80. ⟨10.1016/j.lfs.2015.07.024⟩
- Publication Year :
- 2015
- Publisher :
- Elsevier BV, 2015.
-
Abstract
- International audience; Glioma initiating cells (GICs) represent a subpopulation of tumor cells endowed with self-renewal and multilineage differentiation capacity but also with innate resistance to cytotoxic agents, a feature likely to pose major clinical challenges towards the complete eradication of minimal residual disease in glioma patients. In this work, GICs were obtained from two patient-derived high-grade gliomas xenograft model, expressing differently EGFR. GICs were exposed to anti-EGFR monoclonal antibody cetuximab during 48h in 1% or 21% oxygen tension. Cell viability and self-renewal capacity were then evaluated as well as their angiogenic properties. GICs were sensitive to cetuximab only in normoxic condition whatever the EGFR status. Nevertheless, under hypoxia cetuximab was able to decrease the self-renewal capacity as well as the expression of CD133 while expression of GFAP increased. Moreover, cetuximab decreased the effect of GICs on endothelial cell migration under hypoxia. Consequently, anti-EGFR therapy can be envisaged to target specifically GICs in order to limit the tumor recurrence.
- Subjects :
- Cell Survival
medicine.drug_class
Angiogenesis
Cetuximab
Gene Expression
[SDV.CAN]Life Sciences [q-bio]/Cancer
Monoclonal antibody
General Biochemistry, Genetics and Molecular Biology
Cell Movement
Glioma
Glial Fibrillary Acidic Protein
Tumor Cells, Cultured
medicine
Humans
Viability assay
General Pharmacology, Toxicology and Pharmaceutics
neoplasms
Cell Proliferation
Brain Neoplasms
business.industry
Angiogenesis Modulating Agents
Antibodies, Monoclonal
Endothelial Cells
General Medicine
medicine.disease
Minimal residual disease
Cell Hypoxia
Oxygen tension
ErbB Receptors
Immunology
Monoclonal
Neoplastic Stem Cells
Cancer research
business
medicine.drug
Subjects
Details
- ISSN :
- 00243205
- Volume :
- 137
- Database :
- OpenAIRE
- Journal :
- Life Sciences
- Accession number :
- edsair.doi.dedup.....6014b72b0e94a8c2783bdb59eb380320